AU · rank #11 · 2026-10-22
ALVO
NASDAQ · $1.89B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.462 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.00 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.213 |
| Analyst upside Consensus target $7.20 | +40.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +77.06% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.43 |
| Gross margin TTM | +60.7% |
| 52w high | $8.50 |
| Market cap (USD) | $1.89B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Alvotech is a specialty biopharmaceutical company focused on developing and commercializing generic biologic and monoclonal antibody biosimilar therapies globally.
Rationale
The analyst upside signal is supported by 40.4% target upside and 100% positive 30-day net revisions, backed by recent EMA filings, FDA Reykjavik facility approvals, and reaffirmed $650–700M FY2026 revenue guidance.
Material risks
- 1Regulatory non-approvals, delays, or complete response letters from the FDA or EMA for late-stage pipeline programs, specifically AVT05, AVT06, AVT16, and AVT80.
- 2Rapid biosimilar price erosion and commoditization from competing entrants, exacerbated by high analyst target price dispersion (73.5%) and recent negative earnings surprises (-30.2%).
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.